MTCR - The Race is Heating Up in the $30-plus Billion NASH Treatment Space (MDGL ATRX VKTX ARWR GALT MTCR ICPT GILD)

The race is on to get a commercial biotech treatment asset targeting Nonalcoholic steatohepatitis, or “NASH”. NASH is sadly one of the fastest growing treatable major health problems on the planet right now, and analysts believe the resulting commercial opportunity could be as big as $20-35 billion annually by midway through this decade. NASH is […]

For further details see:

The Race is Heating Up in the $30-plus Billion NASH Treatment Space (MDGL, ATRX, VKTX, ARWR, GALT, MTCR, ICPT, GILD)